Biotech · Private company
Delcath Systems Inc.
Track this companyFree. Adds Delcath Systems Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials85 recruiting or active
Pipeline programs12From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline12
- Cisplatin and GemcitabinePhase 3 · Bile Duct CancerClinicalTrials.gov · fetched Nov 12, 2026
- hepatic artery embolizationPhase 3 · Intraocular MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- melphalanPhase 3 · Intraocular MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS)Phase 3 · Metastatic Ocular MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- Melphalan/HDSPhase 3 · Ocular MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- Melphalan/HDSPhase 3 · Bile Duct CancerClinicalTrials.gov · fetched Nov 12, 2026
- regional chemotherapyPhase 3 · Intraocular MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- systemic chemotherapyPhase 3 · Intraocular MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus BevacizumabPhase 2 · Refractory Metastatic Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- Melphalan/HDS followed by Physician's choice of SOC (eribulin, vinorelbine, or capecitabine)Phase 2 · Metastatic Breast Cancer in the LiverClinicalTrials.gov · fetched Nov 12, 2026
- Physician's choice of SOC (eribulin, vinorelbine, or capecitabine)Phase 2 · Metastatic Breast Cancer in the LiverClinicalTrials.gov · fetched Nov 12, 2026
- Trifluridine-tipiracil plus Bevacizumab AlonePhase 2 · Refractory Metastatic Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials8
- Hepzato Kit and Opdualag for Metastatic Melanoma and Liver MetastasisPHASE1_PHASE2 · RECRUITING · started Nov 1, 2026ClinicalTrials.gov NCT07281924 · fetched Nov 12, 2026
- Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant DiseasePHASE2 · RECRUITING · started Jan 29, 2026ClinicalTrials.gov NCT06875128 · fetched Nov 12, 2026
- Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal MelanomaPHASE2 · RECRUITING · started Dec 31, 2025ClinicalTrials.gov NCT07276386 · fetched Nov 12, 2026
- Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant DiseasePHASE2 · RECRUITING · started Aug 5, 2025ClinicalTrials.gov NCT06607458 · fetched Nov 12, 2026
- An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular MelanomaPHASE3 · ACTIVE_NOT_RECRUITING · started Jun 10, 2022ClinicalTrials.gov NCT05022901 · fetched Nov 12, 2026
- Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic CholangiocarcinomaPHASE2_PHASE3 · UNKNOWN · started Apr 10, 2018ClinicalTrials.gov NCT03086993 · fetched Nov 12, 2026
- Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular MelanomaPHASE3 · COMPLETED · started Feb 1, 2016ClinicalTrials.gov NCT02678572 · fetched Nov 12, 2026
- Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to MelanomaPHASE3 · COMPLETED · started Feb 1, 2006ClinicalTrials.gov NCT00324727 · fetched Nov 12, 2026